Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Brad H Rovin; Dawn J Caster; Daniel C Cattran; Keisha L Gibson; Jonathan J Hogan; Marcus J Moeller; Dario Roccatello; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Jürgen Floege; Conference Participants

doi:10.1016/j.kint.2018.11.008

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

Collaborators

Conference Participants:
Sharon G Adler, Charles E Alpers, Isabelle Ayoub, Arvind Bagga, Sean J Barbour, Jonathan Barratt, Daniel T M Chan, Anthony Chang, Jason Chon Jun Choo, H Terence Cook, Rosanna Coppo, Fernando C Fervenza, Agnes B Fogo, Jonathan G Fox, Richard J Glassock, David Harris, Elisabeth M Hodson, Jonathan J Hogan, Elion Hoxha, Kunitoshi Iseki, J Charles Jennette, Vivekanand Jha, David W Johnson, Shinya Kaname, Ritsuko Katafuchi, A Richard Kitching, Richard A Lafayette, Philip K T Li, Adrian Liew, Jicheng Lv, Ana Malvar, Shoichi Maruyama, Juan Manuel Mejía-Vilet, Chi Chiu Mok, Patrick H Nachman, Carla M Nester, Eisei Noiri, Michelle M O'Shaughnessy, Seza Özen, Samir M Parikh, Hyeong-Cheon Park, Chen Au Peh, William F Pendergraft, Matthew C Pickering, Evangéline Pillebout, Jai Radhakrishnan, Manish Rathi, Pierre Ronco, William E Smoyer, Sydney C W Tang, Vladimír Tesař, Joshua M Thurman, Hernán Trimarchi, Marina Vivarelli, Giles D Walters, Angela Yee-Moon Wang, Scott E Wenderfer, Jack F M Wetzels

Affiliations

¹ Division of Nephrology, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA. Electronic address: [email protected].
² Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.
³ Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
⁴ University of North Carolina Kidney Center at Chapel Hill, Chapel Hill, North Carolina, USA.
⁵ Division of Nephrology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁶ Division of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule, University of Aachen, Aachen, Germany.
⁷ CMID (Center of Research of Immunopathology and Rare Diseases), and Division of Nephrology and Dialysis (ERK-Net member), University of Turin, Italy.
⁸ KDIGO, Brussels, Belgium.
⁹ University College London, London, UK.
¹⁰ Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
¹¹ Division of Nephrology, Rheinisch-Westfälische Technische Hochschule, University of Aachen, Aachen, Germany. Electronic address: [email protected].

PMID: 30665569
DOI: 10.1016/j.kint.2018.11.008

Abstract

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

Keywords: C3 glomerulopathy; KDIGO; anti-neutrophil cytoplasmic antibody–associated vasculitis; focal and segmental glomerulosclerosis; lupus nephritis; membranoproliferative glomerulonephritis; minimal change disease; monoclonal gammopathies of renal significance.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / complications
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / diagnosis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / genetics
Biomarkers / analysis
Consensus Development Conferences as Topic
Disease Progression
Genetic Testing
Glomerular Filtration Rate
Glomerulonephritis / etiology
Glomerulonephritis / pathology
Glomerulonephritis / therapy*
Humans
Nephrology / methods
Nephrology / standards
Nephrosis, Lipoid / etiology
Nephrosis, Lipoid / pathology
Nephrosis, Lipoid / therapy*
Paraproteinemias / complications
Paraproteinemias / diagnosis
Paraproteinemias / genetics
Podocytes / immunology
Podocytes / pathology
Practice Guidelines as Topic*
Risk Factors
Treatment Outcome

Substances

Biomarkers

Grants and funding

212252/Z/18/Z/WT_/Wellcome Trust/United Kingdom